If a hemorrhagic fever bioweapon is released, CD38 inhibitors may be an antidote: Yan

China is repurposing daratumumab, FDA approved for cancer, to combat hantavirus, Lassa, and Marburg viruses, claims scientist

Dr. Li-Meng Yan says China is planning to use a CD38 inhibitor, such as the monoclonal antibody daratumumab — FDA approved as Janssen’s Darzalex — or a similar antibody, as an antidote to hemorrhagic fever (HF) viruses used as bioweapons.

JD Rucker’s video interview with Dr. Yan and his associated article reveal an alleged plan by China to release one or more HF viruses — hantavirus, Lassa, or Marburg — at the current Winter Olympics in Beijing.

These viruses cause horrific disease, with Marburg having a case fatality rate of 23-90%, for example.

Although effective for some hemorrhagic fever viruses, CD38 inhibitors don’t work well for Ebola, says Dr. Yan.

Chinese scientists published a September 2021 paper showing CD38 expression correlates with disease severity in hemorrhagic fever with renal syndrome.

CD38 inhibitors are anti-CD38 monoclonal antibodies used for treating multiple myeloma, a type of blood cancer.

CD38 is a protein primarily found on the surface of multiple myeloma cells.

If CD38 inhibitors are effective as Dr. Yan claims, our leaders should be stockpiling them for use in the event of a hemorrhagic fever outbreak.

Will leaders suppress early treatment of HF as they did for certain drugs effective for Covid?

China not in charge

Despite Dr. Yan’s information, China is almost certainly not running these operations against Western countries, though it could be participating.